Prior authorization for medications

Medication prior authorization is a coverage control: the payer will not pay for a designated drug unless it has reviewed and approved the request against its own rules first. Like other forms of prior authorization, it is a financial and coverage decision, not clinical permission to treat. A prescriber remains free to order a medication; prior authorization only determines whether — and under what conditions — the plan will cover it. The review typically compares the patient's documented clinical picture against the plan's published criteria for that drug, which may reference diagnosis, prior therapies tried, dosing, and site of care.

The most consequential distinction for medication prior authorization is which benefit pays. Drugs a patient takes themselves — filled at a retail, mail-order, or specialty pharmacy — generally run through the pharmacy benefit, often managed by a pharmacy benefit manager and adjudicated in real time at the point of sale. Drugs a clinician administers in an office, clinic, or infusion setting generally run through the medical benefit and are billed on a medical claim after the encounter. The same molecule can sometimes fall under either benefit depending on how it is obtained, so the first step is confirming which benefit and which set of rules applies.

Payers apply prior authorization selectively rather than to every drug. A medication is more likely to require it when a lower-cost or preferred alternative exists, when there are safety or dosing concerns, or when the drug is high-cost or reserved for specific clinical situations. The particular list is defined by each plan and revised on its own schedule.

• Formulary placement — the drug sits on a tier or in a category that the plan gates behind review.
• Step therapy — the plan expects a preferred agent to be tried first before covering an alternative.
• Quantity or dose limits — requests above a set amount or frequency trigger review.
• Safety and appropriateness edits — age, diagnosis, duplicate-therapy, or interaction checks.
• Specialty and high-cost drugs — a plan may place very high-cost drugs on a designated specialty tier and apply review criteria to them.
• Site-of-care rules — the plan may steer administration to a specific, lower-cost setting.

Step therapy

A protocol requiring a patient to try a preferred or lower-cost medication first, and to have it fail or be unsuitable, before the plan covers a different drug. The specific steps vary by payer and plan.

Medical necessity

The standard a payer uses to judge whether a drug is appropriate for the patient's documented condition under its policy. Meeting it is usually central to an approval.

Quantity limit

A cap on the amount or frequency of a drug that the plan will cover without additional review, often tied to labeling or clinical guidelines.

The mechanics resemble any other authorization but center on the drug and the prescriber. The order of operations below is typical; each payer defines its own forms, portals, and required evidence.

1. 01

   Confirm coverage and benefit

   Run eligibility verification and determine whether the drug falls under the pharmacy or medical benefit, then check the applicable formulary or policy for a prior-authorization flag.
2. 02

   Assemble clinical documentation

   Collect the diagnosis, relevant history, prior therapies tried, and supporting notes. Gathering clinical documentation that maps to the plan's published criteria is what usually decides the outcome.
3. 03

   Submit the request

   Complete the payer's drug-specific form and submit the request through its designated channel — often a pharmacy portal for pharmacy-benefit drugs or a medical portal for clinician-administered ones.
4. 04

   Criteria review and decision

   The plan compares the submission against its criteria and issues an approval, a denial, or a request for more information, frequently returning an approval identifier when the drug is authorized.

A decision can be a full approval, a partial approval with limits, or a denial. When a request is denied on clinical grounds, a plan may offer a peer-to-peer review in which the prescriber discusses the case with the plan's reviewer, and a denial can be challenged through the plan's appeal process. The broader mechanics of approvals, denials, and peer-to-peer review apply to drugs as they do to services.

Public programs split drug coverage in ways that shape where prior authorization applies. Under Medicare, clinician-administered drugs generally fall under Part B, while most self-administered outpatient prescription drugs fall under Part D — a structural division that determines which rules and which review process govern a given medication. Medicare Advantage and Part D plans, and state Medicaid programs, each layer their own formularies and utilization rules on top.

One question sits above all of them and is easy to mistake for a formulary problem. Part D's statutory definition excludes certain medical uses from the benefit outright, so for an excluded use there is no formulary placement to review and no criteria to meet — the drug is simply not a Part D drug for that purpose, while the same product remains one for a medically accepted indication that is not excluded. GLP-1 coverage under Medicare works through that distinction on the drug class where it bites hardest, and explains why an authorization request is the wrong instrument when the use itself is outside the benefit.

Because of this, medication prior authorization is best treated as plan-specific. The requirements described here are structural, but the covered drugs, criteria, forms, and timeframes are set by each payer and program and revised regularly. Guidance specific to Medicare Advantage and to Medicaid covers those programs in more depth, and the current payer or program source should always be checked before acting on any specific drug.